Adam S. Brown

TL;DR: A compelling case can be made that TIR is strongly associated with the risk of microvascular complications and should be an acceptable end point for clinical trials.

TL;DR: The authors work toward a multipart solution to facilitate the retention of such a metric, which includes renaming the eA1C the glucose management indicator (GMI) and generating a new formula for converting CGM-derived mean glucose to GMI based on recent clinical trials using the most accurate CGM systems available.

TL;DR: The results suggest that a disturbingly high percentage of people with diabetes experience stigma, particularly those with type 1 or type 2 diabetes who are on intensive insulin therapy, and the experience of stigma disproportionately affects those with a higher BMI, higher A1C, and poorer self-reported blood glucose control.

TL;DR: This report seeks to contribute broader engagement of the diabetes community and a specific focus on regulatory implications of achieving consensus on glycemic outcomes beyond A1C by addressing concerns about inconsistent reporting of CGM-measured outcomes.

TL;DR: The Loop open source system can be initiated with community-developed resources and used safely and effectively by adults and children with type 1 diabetes.